Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Noura J. Choudhury"'
Autor:
Noura J. Choudhury, Antonio Marra, Jane S.Y. Sui, Jessica Flynn, Soo-Ryum Yang, Christina J. Falcon, Pier Selenica, Adam J. Schoenfeld, Natasha Rekhtman, Daniel Gomez, Michael F. Berger, Marc Ladanyi, Maria Arcila, Charles M. Rudin, Gregory J. Riely, Mark G. Kris, Glenn Heller, Jorge S. Reis-Filho, Helena A. Yu
Publikováno v:
Journal of Thoracic Oncology. 18:463-475
Preferred first-line treatment for patients with metastatic EGFR-mutant lung cancer is osimertinib, yet it is not known if patient outcomes may be improved by identifying and intervening upon molecular markers associated with therapeutic resistance.A
Autor:
James P. Solomon, Soo-Ryum Yang, Noura J. Choudhury, Ryan N. Ptashkin, Nasrin Eslamdoost, Christina J. Falcon, Axel Martin, Andrew Plodkowski, Clare Wilhelm, Ronglai Shen, Marc Ladanyi, Michael Berger, Yanming Zhang, Alexander Drilon, Maria E. Arcila
Publikováno v:
Clin Cancer Res
Purpose: Clinical relevance thresholds and laboratory methods are poorly defined for MET amplification, a targetable biomarker across malignancies. Experimental Design: The utility of next-generation sequencing (NGS) in assessing MET copy number alte
Autor:
Noura J. Choudhury, Jessica A. Lavery, Samantha Brown, Ino de Bruijn, Justin Jee, Thinh Ngoc. Tran, Hira Rizvi, Kathryn C. Arbour, Karissa Whiting, Ronglai Shen, Matthew Hellmann, Philippe L. Bedard, Celeste Yu, Natasha Leighl, Michele LeNoue-Newton, Christine Micheel, Jeremy L. Warner, Michelle S. Ginsberg, Andrew Plodkowski, Jeffrey Girshman, Peter Sawan, Shirin Pillai, Shawn M. Sweeney, Kenneth L. Kehl, Katherine S. Panageas, Nikolaus Schultz, Deb Schrag, Gregory J. Riely
Publikováno v:
Clinical Cancer Research.
Purpose: We describe the clinical and genomic landscape of the non-small cell lung cancer (NSCLC) cohort of the AACR Project GENIE Biopharma Collaborative (BPC). Experimental Design: 1,846 patients with NSCLC whose tumors were sequenced from 2014 to
Autor:
Charles M. Rudin, David Balli, W. Victoria Lai, Allison L. Richards, Evelyn Nguyen, Jacklynn V. Egger, Noura J. Choudhury, Triparna Sen, Andrew Chow, John T. Poirier, William J. Geese, Matthew D. Hellmann, Ann Forslund
Publikováno v:
Journal of Thoracic Oncology.
Autor:
Yosef Tobi, Sara A. Hayes, Isabel R Preeshagul, Afsheen Iqbal, Mark G. Kris, Glenn Heller, Noura J. Choudhury, Robert M Daly, Helena A. Yu, Alex Makhnin, Linda S Ahn, Gregory J Riely
Publikováno v:
JCO Precision Oncology. :695-700
PURPOSE Patients with EGFR-mutant lung cancer have no approved targeted therapies after disease progression on first-line osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Preclinical studies sug
Autor:
Monica F. Chen, Allison Richards, Patrick Evans, Patrick Lee, Adam Price, Matteo Repetto, Soo Ryum Yang, Jason Chang, Rose Brannon, Ezra Rosen, David Brown, Charles Rudin, Nitya Raj, Mark G. Kris, Jorge Reis-Filho, Mark Donoghue, Alexander E. Drilon, Noura J. Choudhury
Publikováno v:
Cancer Research. 83:1394-1394
Introduction: The MYC gene family (MYCf), which includes MYC, MYCN, and MYCL, is deregulated in ~70% of cancers and is associated with treatment resistance. Whereas older investigational therapies for MYC amplified tumors were unsuccessful, promising
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Noura J. Choudhury, Alexander Drilon
Publikováno v:
Transl Lung Cancer Res
Targeted therapy has become the standard of care for non-small cell lung cancers with a range of targetable alterations, including ALK and ROS1 kinase fusions. RET fusions drive the oncogenesis of 1–2% of NSCLCs and represent a substantial global b
Autor:
Adrienne Boire, Alexander Drilon, Noura J. Choudhury, Soo-Ryum Yang, Maria E. Arcila, Abhinita Mohanty
Publikováno v:
JCO Precis Oncol
Autor:
Jessica J. Lin, Yunan Nie, Alexia Iasonos, Andrew J. Plodkowski, Maria E. Arcila, Debra A. Goldman, Jaime L. Schneider, Viola W. Zhu, Sai-Hong Ignatius Ou, Natasha Rekhtman, Alexander Drilon, Subba R. Digumarthy, Tejas Patil, Jamie E. Chaft, Christina Falcon, Andrew Do, Noura J. Choudhury, Soo-Ryum Yang
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100187-(2021)
Introduction: ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype ha